Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Aug;19(8):497-498.
doi: 10.1038/s41571-022-00647-9.

Role of neoadjuvant chemoimmunotherapy for resectable NSCLC

Boris Sepesi  1 , Stephen G Swisher  2
Affiliations
Comment

Role of neoadjuvant chemoimmunotherapy for resectable NSCLC

Boris Sepesi et al. Nat Rev Clin Oncol. 2022 Aug.
No abstract available

PubMed Disclaimer

Comment on

  • Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
    Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Forde PM, et al. N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11. N Engl J Med. 2022. PMID: 35403841 Free PMC article. Clinical Trial.

References

    1. Forde, P. M. et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2202170 (2022). - DOI - PubMed
    1. Jiang, J. et al. Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis. Transl. Lung Cancer Res. 11, 277–294 (2022). - DOI
    1. Felip, E. et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 398, 1344–1357 (2021). - DOI
    1. Wu, Y. L. et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 383, 1711–1723 (2020). - DOI
    1. Pisters, K. M. et al. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J. Clin. Oncol. 28, 1843–1849 (2010). - DOI

MeSH terms